Powered by: Motilal Oswal
2024-12-31 11:53:18 am | Source: Choice Broking Ltd
NEW YEAR Pick 2025 by Sumeet Bagadia, Choice Broking Ltd
NEW YEAR Pick 2025 by Sumeet Bagadia, Choice Broking Ltd

Sun Pharmaceutical Industries Limited

SUNPHARMA is currently trading at 1,881 and has recently reversed from a rising trend line, forming Doji candles near the bottom on the weekly chart. This signals a potential reversal and the onset of a strong bullish trend. A breakout above 1,880 could drive the stock towards the 2,055 and Rs 2,150 levels, with immediate resistance at 1,960,
On the downside, critical support levels are identified at Rs 1,800 and Rs 1,780. After a prolonged correction, the stock has rebounded from its support zone. The Relative Strength Index (RSI) is currently at 64.9, indicating an upward trajectory and strengthening buying momentum.
Considering the technical indicators, a prudent strategy would be to look for buying opportunities on dips around the Rs 1,840 and 1,800 levels. Based on the technical analysis and prevailing market conditions, SUNPHARMA presents a promising buying opportunity for traders targeting the Rs 2,055 and 2,150 levels. As always, it is essential to apply sound risk management strategies to mitigate potential market fluctuations.

Buy SUNPHARMA @ 1881 & add Upto 1840 for the Target of 2055/2150

 

Mahindra and Mahindra Ltd

M&M is currently trading at 3.042 and has been consolidating near its all-time high, approaching a breakout from its daily range on the weekly chart. This indicates a potential reversal and the onset of a strong bullish trend. A breakout above Rs 3,095 could propel the stock towards the 3,360 and 3,500 levels, with immediate resistance at 3,200.
On the downside, critical support levels are identified at 2900 and 2790. After a prolonged correction, the stock has rebounded from its support zone. The Relative Strength Index (RSI) is currently at 56.3. indicating an upward trajectory and strengthening buying momentum. Considering these technical indicators, a prudent approach would be to look for buying opportunities on dips around the Rs 2,965 and 2,900 levels.
Based on the technical analysis and prevailing market conditions, M&M offers a promising buying opportunity for traders targeting the 3,360 and 3.500 levels. As always, it is crucial to implement effective risk management strategies to navigate potential market fluctuations.

Buy M&M @ 3042 & add Upto 2965 for the Target of 3360/3500

 

Dalmia Bharat Ltd

DALBHARAT is currently trading at 1,772, moving within a sideways range on the weekly chart. The stock is trading near key support levels, suggesting a possible reversal and the emergence of a strong bullish trend. A breakout above 1,800 could drive the stock toward targets of Rs 1,950 and 2,040, with immediate resistance at Rs 1,900.
On the downside, important support levels are at Rs 1,700 and Rs 1,650. Following a prolonged period of correction, the stock has shown signs of recovery from its support zone. The Relative Strength Index (RSI) is at 45.11, indicating a potential upward move and increasing buying interest. Given the current technical setup, it would be prudent to consider accumulating positions on dips near Rs 1,725 and Rs 1,700.
Technical indicators and market conditions suggest that DALBHARAT presents a compelling buying opportunity for traders aiming for targets of 1,950 and 2,040. As always, employing robust risk management strategies is vital to mitigate market volatility.

Buy DALBHARAT @ 1772 & add Upto 1725 for the Target of 1950/2040

 

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here